Literature DB >> 12477357

Structure-activity relationships of the melanocortin tetrapeptide Ac-His-D-Phe-Arg-Trp-NH2 at the mouse melanocortin receptors. 4. Modifications at the Trp position.

Jerry Ryan Holder1, Zhimin Xiang, Rayna M Bauzo, Carrie Haskell-Luevano.   

Abstract

The melanocortin pathway is involved in the regulation of several physiological functions including skin pigmentation, steroidogenesis, obesity, energy homeostasis, and exocrine gland function. This melanocortin pathway consists of five known G-protein coupled receptors, endogenous agonists derived from the proopiomelanocortin (POMC) gene transcript, the endogenous antagonists Agouti and the Agouti-related protein (AGRP) and signals through the intracellular cAMP signal transduction pathway. The endogenous melanocortin agonists contain the putative message sequence "His-Phe-Arg-Trp," postulated to be important for melanocortin receptor molecular recognition and stimulation. Herein, we report a tetrapeptide library, based upon the template Ac-His-D-Phe-Arg-Trp-NH(2), consisting of 20 members that have been modified at the Trp(9) position (alpha-MSH numbering) and pharmacologically characterized for agonist activity at the mouse melanocortin receptors MC1R, MC3R, MC4R, and MC5R. Results from this study yielded compounds that ranged in pharmacological properties from equipotent to a loss of melanocortin receptor activity at up to 100 microM concentrations. Interestingly, modification of the Trp(9) in the tetrapeptide template at the MC1R resulted in only up to a 220-fold potency change, while at the MC4R and MC5R, up to a 9700-fold decrease in potency was observed, suggesting the MC1R is more tolerant of the modifications examined herein. The most notable results of this study include identification that the Trp(9) indole moiety in the tetrapeptide template is important for melanocortin-3 receptor agonist potency, and that this position can be used to design melanocortin ligands possessing receptor selectivity for the peripherally expressed MC1 and MC5 versus the centrally expressed MC3 and MC4 receptors. Specifically, the Ac-His-D-Phe-Arg-Tic-NH(2) and the Ac-His-D-Phe-Arg-Bip-NH(2) tetrapeptides possessed nanomolar MC1R and MC5R potency but micromolar MC3R and MC4R agonist potency. Additionally, these studies identified that substitution of the Trp amino acid with either Nal(2') or D-Nal(2') resulted in equipotent melanocortin receptor potency, suggesting that the chemically reactive Trp indole side chain may be replaced with the nonreactive Nal(2') moiety for the design of nonpeptide melanocortin receptor agonists.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12477357     DOI: 10.1021/jm020296e

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

1.  Interactions of human melanocortin 4 receptor with nonpeptide and peptide agonists.

Authors:  Irina D Pogozheva; Biao-Xin Chai; Andrei L Lomize; Tung M Fong; David H Weinberg; Ravi P Nargund; Michael W Mulholland; Ira Gantz; Henry I Mosberg
Journal:  Biochemistry       Date:  2005-08-30       Impact factor: 3.162

2.  Melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 modified at the para position of the benzyl side chain (DPhe): importance for mouse melanocortin-3 receptor agonist versus antagonist activity.

Authors:  Bettina Proneth; Irina D Pogozheva; Federico P Portillo; Henry I Mosberg; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

3.  Structure-activity relationships of peptides incorporating a bioactive reverse-turn heterocycle at the melanocortin receptors: identification of a 5800-fold mouse melanocortin-3 receptor (mMC3R) selective antagonist/partial agonist versus the mouse melanocortin-4 receptor (mMC4R).

Authors:  Anamika Singh; Marvin Dirain; Rachel Witek; James R Rocca; Arthur S Edison; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2013-03-25       Impact factor: 7.446

4.  Discovery of a β-Hairpin Octapeptide, c[Pro-Arg-Phe-Phe-Dap-Ala-Phe-DPro], Mimetic of Agouti-Related Protein(87-132) [AGRP(87-132)] with Equipotent Mouse Melanocortin-4 Receptor (mMC4R) Antagonist Pharmacology.

Authors:  Mark D Ericson; Andrzej Wilczynski; Nicholas B Sorensen; Zhimin Xiang; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2015-04-21       Impact factor: 7.446

Review 5.  Novel approaches to the design of bioavailable melanotropins.

Authors:  Yang Zhou; Minying Cai
Journal:  Expert Opin Drug Discov       Date:  2017-07-12       Impact factor: 6.098

6.  Design of MC1R Selective γ-MSH Analogues with Canonical Amino Acids Leads to Potency and Pigmentation.

Authors:  Yang Zhou; Saghar Mowlazadeh Haghighi; Ioanna Zoi; Jonathon R Sawyer; Victor J Hruby; Minying Cai
Journal:  J Med Chem       Date:  2017-11-13       Impact factor: 7.446

7.  Discovery of Melanocortin Ligands via a Double Simultaneous Substitution Strategy Based on the Ac-His-dPhe-Arg-Trp-NH2 Template.

Authors:  Aleksandar Todorovic; Cody J Lensing; Jerry Ryan Holder; Joseph W Scott; Nicholas B Sorensen; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2018-06-11       Impact factor: 4.418

8.  Pharmacological characterization of 30 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists, synthetic agonists, and the endogenous agouti-related protein antagonist.

Authors:  Zhimin Xiang; Bettina Proneth; Marvin L Dirain; Sally A Litherland; Carrie Haskell-Luevano
Journal:  Biochemistry       Date:  2010-06-08       Impact factor: 3.162

9.  Semi-rigid tripeptide agonists of melanocortin receptors.

Authors:  Andrew R Ruwe; Leonid Koikov; Zalfa Abdel-Malek; Carrie Haskell-Luevano; Marvin L Dirain; Federico Portillo; Zhimin Xiang; Matt Wortman; James J Knittel
Journal:  Bioorg Med Chem Lett       Date:  2009-07-09       Impact factor: 2.823

10.  Synthesis and Structure-Activity Relationships of Substituted Urea Derivatives on Mouse Melanocortin Receptors.

Authors:  Anamika Singh; Johannes Kast; Marvin L S Dirain; Huisuo Huang; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2015-12-24       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.